DCPrime
DCPrime is a biotechnology company developing cancer immunotherapies.
All edits
' fill='white' fill-rule='nonzero'%3e%3cpath d='M52 12c-22.048 0-40 17.952-40 40 0 10.848 4.48 21.376 12.288 28.864 7.008 6.752 16.096 10.592 25.792 11.04.48.032.992.096 1.472.096H52c10.336 0 20.128-3.904 27.616-11.04C87.616 73.312 92 63.04 92 52c0-22.048-17.952-40-40-40zm26.912 65.056c-1.472-5.216-8.448-8.032-13.696-10.112l-1.792-.736C60 64.8 60 63.488 60 61.6c0-1.344.672-3.264 1.888-4.416 3.104-2.72 4.736-6.464 4.736-10.816 0-8.8-6.144-15.168-14.624-15.168-8.448 0-14.336 6.24-14.336 15.168 0 4.544 1.536 8.192 4.512 10.816 1.248 1.12 1.792 3.072 1.792 4.416 0 1.344 0 3.008-4.16 4.704-5.12 2.112-11.904 4.992-15.008 10.432C18.688 69.984 15.2 61.12 15.2 52c0-20.288 16.512-36.8 36.8-36.8 20.288 0 36.8 16.512 36.8 36.8 0 9.408-3.52 18.208-9.888 25.056z'/%3e%3c/g%3e%3c/g%3e%3c/svg%3e)
DCPrime is a company that develops clinical stage, novel cancer immunotherapies that are based on their DCOne platform. The company was founded by Ada Kruisbeek in 2006, in Leiden, Zuid-Holland, The Netherlands.
DCPrime's vaccine, the DCP-001, is a cell-based vaccine that is designed to fight against blood cancers known for relapsing in a patient. The product is in PhasePhase II clinical trials for the purpose of treating acute myeloid leukemia. The company is primarily focused on developing therapeutic candidates for treating hematological malignancies that have a high risk of relapse, which would allow patients to avoid repeat treatments of chemotherapy or bone marrow transplants. The trials are being evaluated in patients with AML, who have responded to chemotherapy treatment, but cannot undergo bone marrow transplant procedures.
Find more companies like DCPrime
